Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||0.16%||162.16||0.7%||$1270.30m|
|LLY||Eli Lilly & Co.||0.50%||334.46||1.1%||$1111.09m|
|BMY||Bristol-Myers Squibb Co.||-0.04%||70.21||1.0%||$751.47m|
|MRK||Merck & Co., Inc.||-0.37%||87.11||0.7%||$695.02m|
|ALNY||Alnylam Pharmaceuticals, Inc.||0.00%||202.37||8.2%||$224.83m|
|HZNP||Horizon Therapeutics Plc||0.00%||67.89||5.4%||$188.70m|
|IDXX||IDEXX Laboratories, Inc.||0.00%||346.02||3.9%||$184.33m|
|GBT||Global Blood Therapeutics, Inc.||0.00%||68.49||5.4%||$178.81m|
|SRPT||Sarepta Therapeutics, Inc.||0.00%||114.82||12.4%||$141.73m|
|AKRO||Akero Therapeutics, Inc.||0.00%||39.26||0.0%||$134.17m|
Cellectis SA operates as a clinical stage biotechnological company. The firm operates through the segments: Therapeutics and Plants. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and monogenic diseases. The Plants segment focuses on using Calyxt's proprietary PlantSpringTM technology platform to engineer plant metabolism to produce innovative, high-value, and sustainable materials and products for use in helping customers meet their sustainability targets and financial goals. The company was founded by David J. Sourdive and AndrÃ© Choulika on February 20, 1999 and is headquartered in Paris, France.